IMS 2022 | Impact of sustained MRD negativity and CR after ide-cel in patients with multiple myeloma
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, comments on the findings of a study investigating the impact of the depth of serological and measurable residual disease (MRD) response in patients with multiple myeloma from the KarMMa trial (NCT03361748) who were treated with idecabtagene vicleucel (ide-cel). Overall, the study showed that whilst one month after ide-cel infusion, achieving early and sustained MRD negativity was the only predictor for a better progression-free survival (PFS), both sustained MRD negativity and complete remission (CR) predicted better outcomes at later stages. In addition, the study demonstrated that patients who were MRD negative but showed a reappearance of normal plasma cells had an inferior PFS in comparison to other patients, thereby suggesting reappearance of normal plasma cells as a surrogate for loss of CAR-T functionality. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
